Nova Biomedical continues international expansion with new subsidiary in Brabant

Nova Biomedical is pleased to announce the opening of a new sales, service and distribution subsidiary in Benelux. The new facility demonstrates Nova’s continued growth in the European market and the expansion of Nova’s biotechnology and clinical products in Belgium, the Netherlands and Luxembourg. Located in ‘s-Hertogenbosch, the office location provides excellent access to all areas of Benelux, allowing the new subsidiary to fully support current business and anticipated future growth.

22 June 2021

“The need for this new subsidiary was driven by the widespread adoption of Nova’s BioProfile FLEX2 series of cell culture analyzers and the launch of new clinical products in the Benelux. Customers will benefit from having Nova Biomedical sales and support professionals close at hand. Furthermore, from this strategic subsidiary we can better support expansion into the local clinical market,” said Andy O’Toole, Nova’s Vice President European Operations.

The Brabant Development Agency (BOM) and the Netherlands Foreign Investment Agency (NFIA) supported the company in setting up the company in the Netherlands.

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacture of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. The company employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Benelux, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Taiwan.